FMISO-based Adaptive Radiotherapy for Head and Neck Cancer

Hypoxia occurs in about 80% of head and neck tumors. Based on experimental and clinical data, hypoxia is a useful parameter for pretherapeutic stratification. These radioresistant regions can be detected with FMISO PET/CT. Moreover, hypoxic subvolumes of tumors can be evolving as target volumes for radiotherapy ("dose painting") in hypoxia imaging-based dose escalation.

Trial Details

NCT ID
NCT05348486
Phase
NA
Sponsor
University Hospital Olomouc
Status
RECRUITING
Cancer Type
Head and Neck Cancer
Interventions
  • Dose escalation
Locations (sample)
  • Brno, Czechia|49.19522,16.60796
  • Olomouc, Czechia|49.59552,17.25175
  • Ostrava, Czechia|49.83465,18.28204

Key Eligibility Criteria

  • Pathologically proven new diagnosis of oropharyngeal p16 negative, or laryngeal, hypopharyngeal, oral cavity (independent of p16) squamous cell car…
  • Evaluable tumor burden assessed by computed tomography scan or magnetic resonance imaging, based on RECIST (Response Evaluation Criteria in Solid T…
  • Eligibiity for definitive chemoradiation or hyperfractionated accelerated radiotherapy
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Head and Neck Cancer Trials on Trialify →